Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Tax Provisions (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Tax Provisions for 4 consecutive years, with -$522000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 149.71% to -$522000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 36.04% year-over-year, with the annual reading at $1.8 million for FY2025, 36.04% down from the prior year.
  • Tax Provisions for Q4 2025 was -$522000.0 at Centessa Pharmaceuticals, down from $166000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $1.4 million in Q1 2025, with the low at -$24.1 million in Q2 2023.
  • Average Tax Provisions over 4 years is -$1.3 million, with a median of $323500.0 recorded in 2024.
  • Peak annual rise in Tax Provisions hit 746.25% in 2023, while the deepest fall reached 109222.73% in 2023.
  • Over 4 years, Tax Provisions stood at -$664000.0 in 2022, then surged by 272.29% to $1.1 million in 2023, then dropped by 8.22% to $1.0 million in 2024, then tumbled by 149.71% to -$522000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$522000.0, $166000.0, and $778000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.